ElaineRoslynPeskindMD

Friends of Alzheimer’s Research Professor of Psychiatry and Behavioral Sciences at the University of Washington School of Medicine in Seattle. She is Associate Director of the University of Washington Alzheimer’s Disease Research Center (and Director of its Clinical Core) and Co-Director of the VA Northwest Network Mental Illness Research, Education, and Clinical Center.

Join to view full profile

Dr. Peskind is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Peskind's full profile

Already have an account?

Office
1660 S Columbian Way
# Va
Seattle, WA 98108
Phone+1 206-277-3965

Fax+1 206-277-4856

Education & Training

University of WashingtonResidency, Psychiatry, 1986 - 1990
University of Washington School of MedicineClass of 1986

Certifications & Licensure

WA State Medical License 1988 - 2025
American Board of Psychiatry and Neurology Psychiatry

Clinical Trials

Age-Related Changes in Stress Hormone Regulation Start of enrollment: 2000 Dec 01
Completed
Alzheimer's in Long-Term Care--Treatment for Agitation Start of enrollment: 2001 Jan 01
Completed
Not Applicable
Prazosin vs. Paroxetine in Combat Stress Symptoms in OIF/OEF Returnees Start of enrollment: 2004 Jul 01
Completed
Not Applicable
Do HMG CoA Reductase Inhibitors Affect Abeta Levels? Start of enrollment: 2002 Aug 01
Completed
Phase 4
Cooperative Studies Program #563 - Prazosin and Combat Trauma PTSD Start of enrollment: 2010 Jan 06
Completed
Phase 3
Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease Start of enrollment: 2010 Mar 01
Completed
Not Applicable
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext Start of enrollment: 2013 Mar 01
Completed
Phase 2, Phase 3
The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF) Start of enrollment: 2014 Jan 08
COMPLETED
PHASE2, PHASE3
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo Start of enrollment: 2013 Jul 01
Terminated
Phase 3
Simvastatin for mTBI Start of enrollment: 2013 Sep 16
Completed
Phase 4
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss Start of enrollment: 2014 Feb 28
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

Sex Differences in Apolipoprotein E and Alzheimer Disease Pathology Across Ancestries.
Xiaoyi Xu, Jiseon Kwon, Ruiqi Yan, Catherine Apio, Soomin Song
JAMA Network Open. 2025-03-03
Dispersion-based cognitive intra-individual variability in former American football players: Association with traumatic encephalopathy syndrome, repetitive head impact...
Caroline Altaras, Monica T Ly, Olivia Schultz, William B Barr, Sarah J Banks
The Clinical Neuropsychologist. 2025-01-26
Single- versus two-test criteria for cognitive impairment: associations with CSF and imaging markers in former American football players.
Monica T Ly, Caroline Altaras, Yorghos Tripodis, Charles H Adler, Laura J Balcer
The Clinical Neuropsychologist. 2025-01-20

Press Mentions

A Peek Inside Human Brain Shows a Way It Cleans Out WasteOctober 7th, 2024
Alzheimer’s Gets a New Drug with GalantamineJuly 30th, 2024
New Blood Test Can Detect ‘Toxic’ Protein Years Before Alzheimer’s Symptoms Emerge, Study ShowsDecember 5th, 2022
Join now to see all

Grant Support

Neurobehavior, Neuropathology, and Risk Factors in Alzheimer's DiseaseUNIVERSITY OF WASHINGTON2016–2027
Neurobehavior, Neuropathology, and Risk Factors in Alzheimer's DiseaseUNIVERSITY OF WASHINGTON2016–2027
Neurobehavior, Neuropathology, and Risk Factors in Alzheimer's DiseaseUNIVERSITY OF WASHINGTON2016–2027
Defining the Role of Post-TBI Sleep Disruption in the Development of CTE and Alzheimer's Disease-Related NeuropathologySEATTLE INST FOR BIOMEDICAL/CLINICAL RES2022–2025
Clinical CoreNational Institute On Aging2010–2012
Mild TBI And Biomarkers Of NeurodegenerationVeterans Affairs2011
Prazosin Treatment For Disruptive Agitation In Alzheimer'S DiseaseNational Institute On Aging2009–2011
Core--ClinicalNational Institute On Aging2000–2009
Alzheimer'S In Long Term Propranolol For AgitationNational Institute On Aging2000–2003
Glucocorticoids And APOE-E4 In Aging And Alzheimer'S DiseaseNational Institute On Aging1996–1999